Ayaka Okubo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ayaka Okubo has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Chihaya Maesawa
Division of Tumor Biology, Institute for Biomedical Sciences, Iwate Medical University, Iwate, Japan
1 shared publication - Masahiko Shibazaki
Division of Tumor Biology, Institute for Biomedical Sciences, Iwate Medical University, Iwate, Japan
1 shared publication Miharu Hanada
Department of Nursing Muroran City General Hospital Muroran‐shi Hokkaido Japan
1 shared publicationNaeko Taniguchi
Department of Rehabilitation Muroran City General Hospital Muroran‐shi Hokkaido Japan
1 shared publication- Nobuyuki Arakawa
Department of Dermatology Iwate Medical University School of Medicine Iwate Japan
1 shared publication Saori Kodama
Department of Nursing Muroran City General Hospital Muroran‐shi Hokkaido Japan
1 shared publication
Latest Publications
- 25 May 2026
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (7) , 1020-1025
Factors Associated With Utilization of a Hospital‐Based Self‐Pay Preventive Foot‐Care Clinic in Japan: A Retrospective Observational Study
Japan is a super‐aging society with universal health insurance, but routine preventive foot and nail care is reimbursed only for limited high‐risk conditions. To compare patients using an insurance‐funded foot‐care service with those using a subsequently introduced hospital‐based self‐pay preventive foot‐care clinic and to identify factors associated with self‐pay clinic use. We retrospectively analyzed de‐identified records from an insurance‐funded program (April 2019–March 2023) and a self‐pay preventive clinic (April 2023–March 2025). Group differences were assessed using Welch's t ‐test and chi‐square tests. Independent predictors were estimated by multivariable logistic regression. The analysis included 1741 patients (1157 insurance‐funded and 584 self‐pay). Self‐pay clinic users were older than insurance‐funded service users (mean 76.1 versus 72.8 years) and were more likely to live alone (50.9% versus 27.0%). Older age, living alone, and higher copayment tiers were independently associated with self‐pay clinic use, whereas sex and public assistance status were not. Self‐pay preventive foot‐care clinic use was concentrated among older patients, particularly those living alone. These findings suggest unmet demand for preventive foot and nail care, but do not establish comparative clinical effectiveness or cost‐effectiveness.
- 25 May 2026
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (7) , 1020-1025
Factors Associated With Utilization of a Hospital‐Based Self‐Pay Preventive Foot‐Care Clinic in Japan: A Retrospective Observational Study
Japan is a super‐aging society with universal health insurance, but routine preventive foot and nail care is reimbursed only for limited high‐risk conditions. To compare patients using an insurance‐funded foot‐care service with those using a subsequently introduced hospital‐based self‐pay preventive foot‐care clinic and to identify factors associated with self‐pay clinic use. We retrospectively analyzed de‐identified records from an insurance‐funded program (April 2019–March 2023) and a self‐pay preventive clinic (April 2023–March 2025). Group differences were assessed using Welch's t ‐test and chi‐square tests. Independent predictors were estimated by multivariable logistic regression. The analysis included 1741 patients (1157 insurance‐funded and 584 self‐pay). Self‐pay clinic users were older than insurance‐funded service users (mean 76.1 versus 72.8 years) and were more likely to live alone (50.9% versus 27.0%). Older age, living alone, and higher copayment tiers were independently associated with self‐pay clinic use, whereas sex and public assistance status were not. Self‐pay preventive foot‐care clinic use was concentrated among older patients, particularly those living alone. These findings suggest unmet demand for preventive foot and nail care, but do not establish comparative clinical effectiveness or cost‐effectiveness.
- 3 May 2024
- Published by Wiley in The Journal of Dermatology
- Vol. 51 (8) , 1091-1097
Long‐term follow‐up study of the efficacy of fosravuconazole in the treatment of onychomycosis in elderly patients
Onychomycosis is a chronic and intractable disease whose prevalence increases during aging. In elderly patients, if onychomycosis is left untreated and progresses to a severe stage it may cause functional decline of the lower limbs due to foot pain. This could lead to a decline in activities of daily living and secondary impairment such as cognitive decline. Thus, the treatment of onychomycosis in elderly patients is important. We have previously shown that fosravuconazole is relatively safe and effective for onychomycosis in elderly patients. In the present study, we continued the follow‐up study and investigated the efficacy of re‐administration of fosravuconazole in patients with recurrent onychomycosis. One hundred and twenty‐five patients aged ≥65 years who had been initially diagnosed with onychomycosis at our hospital's dermatology department, and who had responded well to fosravuconazole at 48 weeks after the initial treatment, were followed up until 144 weeks after the start of the initial treatment. Patients who experienced a recurrence within 24 weeks after the start of the follow‐up were assigned to the short‐term recurrence group, and those who experienced a recurrence after 24 weeks were assigned to the long‐term recurrence group. All patients in both groups were re‐treated with fosravuconazole to evaluate its efficacy. The short‐term and long‐term recurrence groups consisted of 17 (14.3%) and 10 (8.4%) patients, respectively. There were no significant differences in mean age and sex ratio between the two groups. There were no serious adverse effects in either group, and the toenail opacity ratio was significantly reduced after 12 weeks of re‐treatment in both groups. The short‐term and long‐term recurrence groups were significantly more likely to have wedge‐shaped onychomycosis and total dystrophic onychomycosis, respectively. The results suggest that re‐administration of fosravuconazole is safe and as effective as the first administration for elderly patients with recurrent onychomycosis. This study was registered at UMIN‐CTR (UMIN000053516).
- 3 May 2024
- Published by Wiley in The Journal of Dermatology
- Vol. 51 (8) , 1091-1097
Long‐term follow‐up study of the efficacy of fosravuconazole in the treatment of onychomycosis in elderly patients
Onychomycosis is a chronic and intractable disease whose prevalence increases during aging. In elderly patients, if onychomycosis is left untreated and progresses to a severe stage it may cause functional decline of the lower limbs due to foot pain. This could lead to a decline in activities of daily living and secondary impairment such as cognitive decline. Thus, the treatment of onychomycosis in elderly patients is important. We have previously shown that fosravuconazole is relatively safe and effective for onychomycosis in elderly patients. In the present study, we continued the follow‐up study and investigated the efficacy of re‐administration of fosravuconazole in patients with recurrent onychomycosis. One hundred and twenty‐five patients aged ≥65 years who had been initially diagnosed with onychomycosis at our hospital's dermatology department, and who had responded well to fosravuconazole at 48 weeks after the initial treatment, were followed up until 144 weeks after the start of the initial treatment. Patients who experienced a recurrence within 24 weeks after the start of the follow‐up were assigned to the short‐term recurrence group, and those who experienced a recurrence after 24 weeks were assigned to the long‐term recurrence group. All patients in both groups were re‐treated with fosravuconazole to evaluate its efficacy. The short‐term and long‐term recurrence groups consisted of 17 (14.3%) and 10 (8.4%) patients, respectively. There were no significant differences in mean age and sex ratio between the two groups. There were no serious adverse effects in either group, and the toenail opacity ratio was significantly reduced after 12 weeks of re‐treatment in both groups. The short‐term and long‐term recurrence groups were significantly more likely to have wedge‐shaped onychomycosis and total dystrophic onychomycosis, respectively. The results suggest that re‐administration of fosravuconazole is safe and as effective as the first administration for elderly patients with recurrent onychomycosis. This study was registered at UMIN‐CTR (UMIN000053516).
- 18 September 2017
- Published by Morressier GmbH
Clarification of cytotoxic mechanism in rhododendrol Verification of correlation between NQO1 polymorphism and incidence of RD-induced leukoderma
Welcome to the largest platform for early-stage research
- 18 September 2017
- Published by Morressier GmbH
Clarification of cytotoxic mechanism in rhododendrol Verification of correlation between NQO1 polymorphism and incidence of RD-induced leukoderma
Welcome to the largest platform for early-stage research
- Open Access
- 5 April 2016
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (4) , e0153181
NAD(P)H:Quinone Oxidoreductase-1 Expression Sensitizes Malignant Melanoma Cells to the HSP90 Inhibitor 17-AAG
The KEAP1-NRF2 pathway regulates cellular redox homeostasis by transcriptional induction of genes associated with antioxidant synthesis and detoxification in response to oxidative stress. Previously, we reported that KEAP1 mutation elicits constitutive NRF2 activation and resistance to cisplatin (CDDP) and dacarbazine (DTIC) in human melanomas. The present study was conducted to clarify whether an HSP90 inhibitor, 17-AAG, efficiently eliminates melanoma with KEAP1 mutation, as the NRF2 target gene, NQO1, is a key enzyme in 17-AAG bioactivation. In melanoma and non-small cell lung carcinoma cell lines with or without KEAP1 mutations, NQO1 expression and 17-AAG sensitivity are inversely correlated. NQO1 is highly expressed in normal melanocytes and in several melanoma cell lines despite the presence of wild-type KEAP1, and the NQO1 expression is dependent on NRF2 activation. Because either CDDP or DTIC produces reactive oxygen species that activate NRF2, we determined whether these agents would sensitize NQO1-low melanoma cells to 17-AAG. Synergistic cytotoxicity of the 17-AAG and CDDP combination was detected in four out of five NQO1-low cell lines, but not in the cell line with KEAP1 mutation. These data indicate that 17-AAG could be a potential chemotherapeutic agent for melanoma with KEAP1 mutation or NQO1 expression.
- 5 April 2016
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (4) , e0153181
Open AccessNAD(P)H:Quinone Oxidoreductase-1 Expression Sensitizes Malignant Melanoma Cells to the HSP90 Inhibitor 17-AAG
The KEAP1-NRF2 pathway regulates cellular redox homeostasis by transcriptional induction of genes associated with antioxidant synthesis and detoxification in response to oxidative stress. Previously, we reported that KEAP1 mutation elicits constitutive NRF2 activation and resistance to cisplatin (CDDP) and dacarbazine (DTIC) in human melanomas. The present study was conducted to clarify whether an HSP90 inhibitor, 17-AAG, efficiently eliminates melanoma with KEAP1 mutation, as the NRF2 target gene, NQO1, is a key enzyme in 17-AAG bioactivation. In melanoma and non-small cell lung carcinoma cell lines with or without KEAP1 mutations, NQO1 expression and 17-AAG sensitivity are inversely correlated. NQO1 is highly expressed in normal melanocytes and in several melanoma cell lines despite the presence of wild-type KEAP1, and the NQO1 expression is dependent on NRF2 activation. Because either CDDP or DTIC produces reactive oxygen species that activate NRF2, we determined whether these agents would sensitize NQO1-low melanoma cells to 17-AAG. Synergistic cytotoxicity of the 17-AAG and CDDP combination was detected in four out of five NQO1-low cell lines, but not in the cell line with KEAP1 mutation. These data indicate that 17-AAG could be a potential chemotherapeutic agent for melanoma with KEAP1 mutation or NQO1 expression.